Evidence map›Paper›PMID 36519544›Full record

ArticleThe Journal of clinical investigation2022

A humanized mouse model to study NK cell biology during HIV infection.

Jocelyn T Kim, Jerome A Zack

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Jocelyn T KimDepartment of Medicine, David Geffen School of Medicine.
Jerome A ZackDepartment of Microbiology, Immunology, and Molecular Genetics, and.
University of California, Los Angeles · US

Funding

CRISPR for CureUM1AI164568 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI Tricia Helen Burdo, Kamel Khalili · 2021 to 2026
$27.7M
UCLA-CDU CFARP30AI152501 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, LaShonda Spencer · 2022 to 2026
$15.6M
Natural killer cell engineering to target the HIV reservoirR01AI161803 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BLISH, CATHERINE A, ZACK, JEROME A. · 2021 to 2025
$3.8M
The Effect of Natural Killer Cell-Based Therapy on the HIV ReservoirK08AI155232 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KIM, JOCELYN T · 2020 to 2024
$1.0M
NIAID NIH HHS K08 AI155232NIAID NIH HHS P30 AI152501NIAID NIH HHS R01 AI161803NIAID NIH HHS UM1 AI164568
6 · The paper itself

Abstract

NK cells are an important subset of innate immune effectors with antiviral activity. However, NK cell development and immune responses in different tissues during acute and chronic HIV infection in vivo have been difficult to study due to the impaired development and function of NK cells in conventional humanized mouse models. In this issue of the JCI, Sangur et al. report on a transgenic MISTRG-6-15 mouse model with human IL-6 and IL-15 knocked into the previously constructed MISTRG mice. The predecessor model was deficient in Rag2 and γ chain (γc) with knock-in expression of human M-CSF, IL-3, GM-CSF, and TPO, and transgenic expression of human SIRPα. The researchers studied tissue-specific NK cell immune responses during HIV infection and clearly show that the endogenous human NK cells in the humanized mouse model suppressed HIV-1 replication in vivo. These findings provide insight into harnessing the innate immune response for clinical antiviral therapies.

Indexed as

HIV-1HIV InfectionsAnimalsAntiviral AgentsDisease Models, AnimalHumansKiller Cells, NaturalMiceMice, TransgenicAntiviral Agents

Identifiers

PMID36519544
PMCPMC9753985
OpenAlexW4311442923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.